145 related articles for article (PubMed ID: 36661315)
1. Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study.
Kim WS; Fukuhara N; Yoon DH; Yamamoto K; Uchida T; Negoro E; Izutsu K; Terui Y; Nakajima H; Ando K; Suehiro Y; Kang HJ; Ko PS; Nagahama F; Sonehara Y; Nagai H; Tien HF; Kwong YL; Tobinai K
Blood Adv; 2023 Sep; 7(17):4903-4912. PubMed ID: 36661315
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological profile and clinical study results of darinaparsin (DARVIAS
Yao K; Sonehara Y; Nagahama F
Nihon Yakurigaku Zasshi; 2023; 158(5):408-418. PubMed ID: 37673618
[TBL] [Abstract][Full Text] [Related]
3. Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea.
Ogura M; Kim WS; Uchida T; Uike N; Suehiro Y; Ishizawa K; Nagai H; Nagahama F; Sonehara Y; Tobinai K
Jpn J Clin Oncol; 2021 Feb; 51(2):218-227. PubMed ID: 33051668
[TBL] [Abstract][Full Text] [Related]
4. Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Negoro E; Yamauchi T; Fukuhara N; Yamamoto K; Uchida T; Izutsu K; Maruyama D; Terui Y; Nakajima H; Ando K; Suehiro Y; Choi I; Kanemura N; Nakamura N; Yamamoto G; Maeda Y; Shibayama H; Nagahama F; Sonehara Y; Nagai H; Tien HF; Kwong YL; Kim WS; Tobinai K
J Clin Exp Hematop; 2023; 63(2):108-120. PubMed ID: 37380467
[TBL] [Abstract][Full Text] [Related]
5. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Izutsu K; Makita S; Nosaka K; Yoshimitsu M; Utsunomiya A; Kusumoto S; Morishima S; Tsukasaki K; Kawamata T; Ono T; Rai S; Katsuya H; Ishikawa J; Yamada H; Kato K; Tachibana M; Kakurai Y; Adachi N; Tobinai K; Yonekura K; Ishitsuka K
Blood; 2023 Mar; 141(10):1159-1168. PubMed ID: 36150143
[TBL] [Abstract][Full Text] [Related]
6. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
[TBL] [Abstract][Full Text] [Related]
7. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
Maruyama D; Tobinai K; Ogura M; Uchida T; Hatake K; Taniwaki M; Ando K; Tsukasaki K; Ishida T; Kobayashi N; Ishizawa K; Tatsumi Y; Kato K; Kiguchi T; Ikezoe T; Laille E; Ro T; Tamakoshi H; Sakurai S; Ohtsu T
Int J Hematol; 2017 Nov; 106(5):655-665. PubMed ID: 28664499
[TBL] [Abstract][Full Text] [Related]
9. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
[TBL] [Abstract][Full Text] [Related]
10. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
Barr PM; Li H; Spier C; Mahadevan D; LeBlanc M; Ul Haq M; Huber BD; Flowers CR; Wagner-Johnston ND; Horwitz SM; Fisher RI; Cheson BD; Smith SM; Kahl BS; Bartlett NL; Friedberg JW
J Clin Oncol; 2015 Jul; 33(21):2399-404. PubMed ID: 26077240
[TBL] [Abstract][Full Text] [Related]
11. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
Rai S; Kim WS; Ando K; Choi I; Izutsu K; Tsukamoto N; Yokoyama M; Tsukasaki K; Kuroda J; Ando J; Hidaka M; Koh Y; Shibayama H; Uchida T; Yang DH; Ishitsuka K; Ishizawa K; Kim JS; Lee HG; Minami H; Eom HS; Kurosawa M; Lee JH; Lee JS; Lee WS; Nagai H; Shindo T; Yoon DH; Yoshida S; Gillings M; Onogi H; Tobinai K
Haematologica; 2023 Mar; 108(3):811-821. PubMed ID: 36200417
[TBL] [Abstract][Full Text] [Related]
12. Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study.
Hong X; Song Y; Huang H; Bai B; Zhang H; Ke X; Shi Y; Zhu J; Lu G; Liebscher S; Cai C
Target Oncol; 2019 Apr; 14(2):149-158. PubMed ID: 30904980
[TBL] [Abstract][Full Text] [Related]
13. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study.
Liu Y; Song Y; Zuo S; Zhang X; Liu H; Wang J; Wang J; Tang Y; Zheng W; Ying Z; Ping L; Zhang C; Wu M; Zhu J; Xie Y
Front Immunol; 2023; 14():1128172. PubMed ID: 37081867
[TBL] [Abstract][Full Text] [Related]
15. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
Lee HZ; Kwitkowski VE; Del Valle PL; Ricci MS; Saber H; Habtemariam BA; Bullock J; Bloomquist E; Li Shen Y; Chen XH; Brown J; Mehrotra N; Dorff S; Charlab R; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
Clin Cancer Res; 2015 Jun; 21(12):2666-70. PubMed ID: 25802282
[TBL] [Abstract][Full Text] [Related]
17. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
[TBL] [Abstract][Full Text] [Related]
18. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.
Ravi D; Bhalla S; Gartenhaus RB; Crombie J; Kandela I; Sharma J; Mazar A; Evens AM
Clin Cancer Res; 2014 Dec; 20(23):6023-33. PubMed ID: 25316819
[TBL] [Abstract][Full Text] [Related]
19. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.
Ogura M; Imaizumi Y; Uike N; Asou N; Utsunomiya A; Uchida T; Aoki T; Tsukasaki K; Taguchi J; Choi I; Maruyama D; Nosaka K; Chen N; Midorikawa S; Ohtsu T; Tobinai K
Lancet Haematol; 2016 Mar; 3(3):e107-18. PubMed ID: 26947199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
